These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11714203)

  • 1. Susceptibility of pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis.
    Robinson CA; Kuhn RJ; Craigmyle J; Anstead MI; Kanga JE
    Pharmacotherapy; 2001 Nov; 21(11):1320-4. PubMed ID: 11714203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Christenson JC; Korgenski EK; Daly JA
    J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
    Ramphal R; Hoban DJ; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 Feb; 36(2):125-9. PubMed ID: 10705055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa.
    Aubert D; Poirel L; Chevalier J; Leotard S; Pages JM; Nordmann P
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1615-20. PubMed ID: 11353602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
    Bonfiglio G; Marchetti F
    Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1991 Apr; 35(4):783-4. PubMed ID: 1906264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.
    Dalzell AM; Sunderland D; Hart CA; Heaf DP
    Thorax; 1991 Apr; 46(4):239-41. PubMed ID: 1903896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro activity of three anti-pseudomonal cephalosporins against isolates from patients with cystic fibrosis.
    Kelly N; Falkiner FR; Keane CT; Murphy M; Fitzgerald MX
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():175-8. PubMed ID: 19802982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL
    Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance evaluation of the βLACTA™ Test for rapid detection of ceftazidime resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Ract P; Dahoumane R; Gallah S; Morand P; Podglajen I; Compain F
    J Microbiol Methods; 2019 Mar; 158():21-24. PubMed ID: 30708085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis].
    Massoni-Cristante S; Loiez C; Adriensen B; Husson MO
    Pathol Biol (Paris); 2003 Apr; 51(3):135-42. PubMed ID: 12781793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.
    Bantar C; Di Chiara M; Nicola F; Relloso S; Smayevsky J
    Diagn Microbiol Infect Dis; 2000 May; 37(1):41-4. PubMed ID: 10794939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime.
    Campo Esquisabel AB; Rodríguez MC; Campo-Sosa AO; Rodríguez C; Martínez-Martínez L
    Clin Microbiol Infect; 2011 Dec; 17(12):1817-22. PubMed ID: 21599797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Li Y; Zhang X; Wang C; Hu Y; Niu X; Pei D; He Z; Bi Y
    Mol Med Rep; 2015 Jan; 11(1):494-8. PubMed ID: 25323940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Manduru M; Mihm LB; White RL; Friedrich LV; Flume PA; Bosso JA
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2053-6. PubMed ID: 9303416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.